Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
2016 · Nature Communications · 650 citations
https://doi.org/10.1038/ncomms11815
G
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
443
Papers
30.6K
Citations
79
h-index
204
i10-index
Gregory A. Otterson is an academic researcher from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Lung Cancer Research Studies. The author has an h-index of 79, co-authored 377 publications.
ORCID: 0000-0001-9877-8512Papers by this author
worksNCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
2023 · Journal of the National Comprehensive Cancer Network · 449 citations
https://doi.org/10.6004/jnccn.2023.0020
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
2019 · The Lancet Oncology · 361 citations
https://doi.org/10.1016/s1470-2045(19)30407-3
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
2021 · Journal of Thoracic Oncology · 318 citations
https://doi.org/10.1016/j.jtho.2021.09.010
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
2014 · Annals of Oncology · 220 citations
https://doi.org/10.1093/annonc/mdt572
Lung cancer exosomes as drivers of epithelial mesenchymal transition
2016 · Oncotarget · 178 citations
https://doi.org/10.18632/oncotarget.10243
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat